Literature DB >> 20532721

Castration-refractory prostate cancer: New drugs in the pipeline.

Dirk Schrijvers1, Peter Van Erps, Jim Cortvriend.   

Abstract

The standard treatment for patients with castration-refractory prostate cancer (CRPC) is the combination docetaxel-prednisone, if the patient can support chemotherapy. Several new treatments have been tested in chemotherapy-naïve or docetaxel-pretreated patients with CRPC. Some of these treatments have shown activity in first-line and second-line treatment. In this review, an update is given of new treatment studies performed in patients with CRPC.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20532721     DOI： 10.1007/s12325-010-0038-1

Source DB:  PubMed          Journal:  Adv Ther        ISSN： 0741-238X            Impact factor:   3.845


  8 in total

1.  Withanolides from Aeroponically Grown Physalis peruviana and Their Selective Cytotoxicity to Prostate Cancer and Renal Carcinoma Cells.

Authors:  Ya-Ming Xu; E M Kithsiri Wijeratne; Ashley L Babyak; Hanna R Marks; Alan D Brooks; Poonam Tewary; Li-Jiang Xuan; Wen-Qiong Wang; Thomas J Sayers; A A Leslie Gunatilaka
Journal:  J Nat Prod       Date:  2017-06-15       Impact factor: 4.050

2.  Ganoderic Acid DM: An Alternative Agent for the Treatment of Advanced Prostate Cancer.

Authors:  Benjamin M Johnson; Bently P Doonan; Faisal F Radwan; Azizul Haque
Journal:  Open Prost Cancer J       Date:  2010-01-01

3.  Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.

Authors:  Jie Li; Anju Karki; Kurt B Hodges; Nihal Ahmad; Amina Zoubeidi; Klaus Strebhardt; Timothy L Ratliff; Stephen F Konieczny; Xiaoqi Liu
Journal:  Mol Cell Biol       Date:  2015-10-05       Impact factor: 4.272

4.  Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer.

Authors:  Xueying Mao; Lara K Boyd; Rafael J Yáñez-Muñoz; Tracy Chaplin; Liyan Xue; Dongmei Lin; Ling Shan; Daniel M Berney; Bryan D Young; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2011-04-15       Impact factor: 6.166

5.  Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis.

Authors:  Lei Wang; Jeffrey Ho; Carlotta Glackin; Manuela Martins-Green
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

6.  Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer.

Authors:  Chu-Biao Zhao; Ji-Ming Bao; Yong-Jie Lu; Tong Zhao; Xin-Hua Zhou; Da-Yong Zheng; Shan-Chao Zhao
Journal:  Am J Cancer Res       Date:  2014-07-16       Impact factor: 6.166

7.  Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer.

Authors:  Xianzeng Hou; Zhiguo Li; Weize Huang; Jiejie Li; Christopher Staiger; Shihuan Kuang; Tim Ratliff; Xiaoqi Liu
Journal:  Prostate       Date:  2013-05-09       Impact factor: 4.104

8.  An update on the changing indications for androgen deprivation therapy for prostate cancer.

Authors:  Kristene Myklak; Shandra Wilson
Journal:  Prostate Cancer       Date:  2011-02-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.